Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting

Pianpian Cao, PhD, MPH,1,‡ Laney Smith, BS,2,‡ Jeanne S. Mandelblatt, MD, MPH,2 Jihyoun Jeon, PhD,1 Kathryn L. Taylor, PhD,2 Amy Zhao, MS,2 David T. Levy, PhD,2 Randi M. Williams, PhD,2 Rafael Meza, PhD,1 Jinani Jayasekera, PhD,1; on behalf of the Lung Screening, Tobacco and Health Trial and the Cancer Intervention and Surveillance Modeling Network

1Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA; and 2Department of Oncology, Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA

‡Authors contributed equally to this work.
*Correspondence to: Pianpian Cao, PhD, Department of Epidemiology, University of Michigan, 1415 Washington Heights, Ann Arbor, MI 48105, USA (e-mail: caop@umich.edu).

Abstract

**Background:** There are limited data on the cost-effectiveness of smoking cessation interventions in lung cancer screening settings. We conducted an economic analysis embedded in a national randomized trial of 2 telephone counseling cessation interventions.

**Methods:** We used a societal perspective to compare the short-term cost per 6-month bio-verified quit and long-term cost-effectiveness of the interventions. Trial data were used to micro-cost intervention delivery, and the data were extended to a lifetime horizon using an established Cancer Intervention Surveillance and Modeling Network lung cancer model. We modeled the impact of screening accompanied by 8 weeks vs 3 weeks of telephone counseling (plus nicotine replacement) vs screening alone based on 2021 screening eligibility. Lifetime downstream costs (2021 dollars) and effects (life-years gained, quality-adjusted life-years [QALYs]) saved were discounted at 3%. Sensitivity analyses tested the effects of varying quit rates and costs; all analyses assumed nonrelapse after quitting.

**Results:** The costs for delivery of the 8-week vs 3-week protocol were $380.23 vs $144.93 per person, and quit rates were 7.14% vs 5.96%, respectively. The least costly strategy was a 3-week counseling approach. An 8-week (vs 3-week) counseling approach increased costs but gained QALYs for an incremental cost-effectiveness ratio of $4029 per QALY. Screening alone cost more and saved fewer QALYs than either counseling strategy. Conclusions were robust in sensitivity analyses.

**Conclusions:** Telephone-based cessation interventions with nicotine replacement are considered cost-effective in the lung screening setting. Integrating smoking cessation interventions with lung screening programs has the potential to maximize long-term health benefits at reasonable costs.

Lung cancer is the leading cause of cancer death in the United States (1). Lung cancer mortality can be reduced by 20%-24% with screening and treatment of early-stage disease (2,3). Based on the US Preventive Services Task Force (USPSTF) early recommendations (4), about 8 million individuals in the United States were eligible for screening, one-half of whom were individuals who currently smoke (5). The USPSTF recently changed the eligibility criteria to earlier ages and broader cigarette use patterns (6), increasing the number of smokers who can benefit from cessation services.

Screening can be a teachable moment, providing the opportunity to motivate individuals who currently smoke to quit (7-11). Smoking cessation can lower cancer incidence and overall tobacco-related mortality (12-14), but there are limited data to guide implementation of smoking cessation programs in lung cancer screening settings. The telephone-based counseling approach has been effective in other settings among older smokers (15-20), smokers who are not ready to quit (21-24), and smokers who are not actively seeking cessation support (22,25,26). Telephone counseling can also assist those who are ready to quit by providing tailored support and information (23,26-32).

Prior studies have suggested that smoking cessation interventions offered at the point of screening could be cost-
effective (13,33-35). However, those investigations used data from many interventions in general populations of smokers and may not reflect the economic outcomes of telephone counseling and other interventions implemented in or via referral from lung cancer screening facilities. Ongoing clinical trials in the lung screening setting are beginning to provide data on intervention efficacy and will be useful to inform dissemination and implementation efforts (7). However, the results of these trials will take years to be known. In this situation, modeling can be useful to extend early trial results to project population effects.

We used data from a multisite national randomized trial (36,37) conducted within the National Cancer Institute–funded Smoking Cessation at Lung Examination initiative to evaluate the short-term societal costs of telephone counseling with nicotine replacement among individuals receiving lung cancer screening. Trial data were extended using a well-established Cancer Intervention and Surveillance Modeling Network (CISNET) microsimulation model to project the lifetime impact (12-14,38). The results are intended to inform discussions about dissemination and integration of cost-effective cessation approaches for smokers receiving lung cancer screening.

Methods

Georgetown Lung Screening, Tobacco, and Health Randomized Trial

This trial evaluated the impact of an 8-week vs 3-week telephone-based counseling intervention with nicotine replacement on smoking cessation among participants recruited between May 2017 and January 2021 from 8 US lung cancer screening facilities. Study procedures were approved by the Georgetown University and Lahey Hospital and Medical Center institutional review boards. Details of the trial have been published elsewhere (36).

Briefly, participants were smokers (cigarettes, cigarillos, or little cigars) who met the National Comprehensive Cancer Network’s eligibility criteria for lung cancer screening (aged 50-80 years with 20+ pack-years) in place of the start of the trial (39). All participants were eligible for screening under the USPSTF 2021 guidelines, and so we chose to extend findings based on the 2021 guidelines (6). Participants were randomly assigned to either 8 weeks of counseling with an 8-week supply of nicotine replacement therapy or 3 weeks of counseling with a 2-week supply of nicotine replacement therapy. We used bio-verified 7-day point prevalence cessation outcomes at 6 months post random assignment for our main analyses and used 12-month prevalence in sensitivity analyses.

CISNET Simulation Model

We used the CISNET University of Michigan lung cancer smoking and screening model (12-14,38) and the CISNET Smoking History Generator (40-42) to extend the trial results to project the lifetime impact of lung screening with 3 vs 8 weeks of telephone counseling and use of nicotine replacement vs screening alone. Model inputs are summarized on Table 1. The model is a population microsimulation model that simulates risk of developing lung cancer on the basis of age and smoking history. Among those who develop lung cancer, lung cancer–specific mortality is based on sex, age, histology, and stage. Lung cancer incidence and mortality can be modified by screening and smoking cessation in the 2 or more years before cancer development, leading to stage shifts and improved survival. At any time, individuals can die of other-cause competing mortality because of other tobacco-related conditions (eg, chronic obstructive pulmonary disease, cardiovascular disease) or non–tobacco-related conditions; smoking cessation may also lower other-cause mortality (Supplementary Methods, available online). The model has been validated against national lung screening trials (38) and observed US mortality and incidence rates (13,43).

We simulated the smoking histories of 1 million men and 1 million women from the 1960 US birth cohort from age 45 to 90 years. We selected this cohort because they have smoking patterns representative of the current US population eligible for lung cancer screening. We started the simulations at age 45 years to generate the population alive at the time of first eligibility for lung screening. Whereas the model follows each person until death, we report results through age 90 years because few cases or smokers are alive beyond 90 years. Smoking history for each person includes age at starting smoking, age at quitting smoking (if quit), and the number of daily cigarettes smoked at each age while smoking. These data are used to determine lung cancer screening eligibility. We modeled 100% screening uptake and adherence under screening eligibility based on USPSTF 2021 guidelines (6) and 100% participation of the cessation program.

The trial data were used to estimate cessation rates among lung screening participants (37). Because the trial did not have a no-intervention arm, we used self-reported data from the Tobacco Use Supplement to the Current Population Survey 2018-2019 to estimate rates expected without specific intervention (Supplementary Methods; Supplementary Table 1, available online) (44). We then applied the relative risk of quitting smoking observed in the trial to this background rate of cessation (Table 1; Supplementary Table 1, available online).

Costs

Costs were collected from the societal perspective. The telephone counseling cessation interventions were micro-costed based on delivery costs at steady state and did not include research or development costs. Costs (2021 dollars) included fixed costs and variable costs per participant (eg, delivering counseling for cessation and time of the participants in receiving counseling) and wholesale costs of nicotine replacement therapy (45). Time costs were valued based on US wage rates for the US Bureau of Labor Statistics (46).

Lung cancer screening and diagnostic costs included Medicare reimbursement rates for screening and follow-up procedures (47). Costs of lung cancer treatments by age, stage, histology, and phase of care (initial, continuing, and terminal) were based on Surveillance, Epidemiology, and End Results Program–Medicare data for smokers, with costs inflated to 2021 US dollars using a 3% annual inflation rate (47,48). We used Medicare costs for all lung cancer screening-eligible individuals; we did not consider costs of care for other tobacco-related diseases or patient time costs for screening and diagnosis.

Utility Values

The age- and sex-specific utilities of smokers without lung cancer were based on a recent study (47). Among those who
developed lung cancer, we added lung cancer–specific utilities based on age, sex, histology (small cell vs non-small cell), stage (limited and extended for small cell and I, II, III, IV for non-small cell) and phase (initial, continuous, and terminal) (47).

Table 1. Model input parameters used to project the lifetime health outcomes with a telephone counseling intervention delivery with lung cancer screening vs screening alone

| Parameters | Description | Reference(s) |
|------------|-------------|--------------|
| Lung cancer incidence risk | A dose-response mechanistic model uses age-specific smoking history as input to generate age-specific lung cancer incidence risk | Meza, et al. (74) |
| Lung cancer histology | Based on a multinomial logistic regression prediction model based on the PLCO control arm with sex, BMI, personal history of cancer, family history of lung cancer, history of COPD, and smoking history as predictors | Caverly, et al. (38) |
| Lung cancer stage | Distribution by histology and sex obtained from SEER 18, 2010-2014 data | Caverly, et al. (38) |
| Preclinical sojourn time | Weibull distribution with shape and scale parameters depending on sex, stage, and histology using PLCO and NLST data | ten Haaf, et al. (75) |
| Screening test performance | Sensitivity of low-dose computerized tomography screen by stage, histology, and screening round; modified to reflect Lung-RADS; specificity by screening round from Lung-RADS | ten Haaf, et al. and Pinsky, et al. (75,76) |
| Lung cancer–specific mortality | Conditioned on sex, age group, histology, and stage using SEER 18 data and Cancer Survival Analysis software | Caverly, et al. and Meza, et al. (38,43) |
| Other-cause–specific mortality | Using the other-cause mortality age output from the Smoking History Generator | Holford, et al. and Holford, et al. (40,41) |
| Screening follow-up and diagnostic procedures | Probabilities of follow-up testing, diagnostic procedures, complications, and diagnostic mortality obtained from NLST | Aberle, et al. and Aberle, et al. (2,77) |
| Lung cancer treatment costs | Age, stage, and phase-specific of care treatment costs based on SEER-Medicare data from 2000-2013 inflated to 2021 US dollars with a 3% inflation rate | Criss, et al., Toumazis, et al. and Sheehan, et al. (47,48,78) |
| Screening procedure costs ($) | Inflated to 2021 US dollars with a 3% inflation rate | Criss, et al., Toumazis, et al. and Sheehan, et al. (47,48,78) |
| Baseline utilities | Conditioned on sex and age | Criss, et al. (47) |
| Lung cancer–specific utilities | Conditioned on lung cancer histology and stage | Criss, et al. (47) |
| Background bio-verified cessation rates in absence of specific interventions*, % (95% CI) | 2.62 (2.29 to 3.00) | Division of Cancer Control and Population Sciences (DCCPS) (44) |
| Smoking cessation bio-verified rates, % (95% CI) | 5.96 (3.65 to 8.27) | |
| 3-wk counseling | 5.96 (3.65 to 8.27) | |
| 8-wk counseling | 7.14 (4.63 to 9.63) | |
| Smoking cessation intervention bio-verified relative risk, mean % (95% CI)b | 2.27 (1.39 to 3.16) | |
| 3-wk counseling | 2.27 (1.39 to 3.16) | |
| 8-wk counseling | 2.72 (1.77 to 3.68) | |
| Smoking cessation intervention costs, mean (range)c | $144.93 (116.91-172.96) | |
| 3-wk counseling | $144.93 (116.91-172.96) | |
| 8-wk counseling | $380.23 (310.80-449.64) | |

*aNational rates of self-reported cessation rates were based on data from the Tobacco Use Supplement to the Current Population Survey 2018-2019 data as 3.97%. To estimate bio-verified rates, we applied the ratio of cessation in the RCT of bio-verified to self-reported rates (0.66) to estimate national bio-verified background cessation. Further details were presented in the Supplementary Methods and Supplementary Table 1 (available online). BMI = body mass index; CI = confidence interval; COPD = chronic obstructive pulmonary disease; Lung-RADS = Lung Imaging Reporting and Data System; NLST = National Lung Screening Trial; PLCO = Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; RCT = randomized controlled trial; SEER = Surveillance, Epidemiology, and End Results.

*bDerived from observed quit rates in the RCT.

cSee Table 2 for derivation.

Statistical Analyses

We compared the average and incremental short-term costs per 6-month bio-verified quit rate for the 8-week vs 3-week telephone
counseling strategy. In sensitivity analyses, we varied quit rates across the upper and lower bounds of intervention efficacy, combinations of cost ranges and efficacy (eg, highest efficacy and lowest costs; lowest efficacy and highest costs), and bio-verified quit rates at 12-month follow-up. Additionally, we varied the background no-intervention quit rates in the Tobacco Use Supplement to the Current Population Survey over its 95% confidence interval.

The simulation model extended the trial results to evaluate the impact of the trial’s cessation interventions over a lifetime horizon. The results were compared across the 3 strategies using incremental cost-effectiveness ratios, where results are arrayed from the least to the costliest strategies and then the added quality-adjusted life-years (QALYs) gained in the next-most costly strategy is divided by its added costs. If a strategy costs more and has fewer QALYs, it is considered dominated because it would not be a recommended approach. If a strategy costs less and gains more life-years, it is considered cost-saving. We used the results of the sensitivity analysis of short-term costs per quit per trial arm to test the impact of these different assumptions on conclusions about the incremental ranking and magnitude of costs per QALY.

Results

Short-Term Trial Costs and Costs per Quit

An 8-week telephone counseling intervention accompanied by nicotine replacement therapy in the setting of lung screening was 2.6 times more costly per person than a 3-week regimen with nicotine replacement therapy (Table 2). The time costs of counselor wages ($107.64 vs $43.31 per person) and differences in amount of nicotine replacement ($110.16 vs $27.54 per person) accounted for most differences in costs between the 2 strategies. Although the 8-week strategy had a higher quit rate than the 3-week strategy (7.14% vs 5.96%), it had higher costs per quit than the 3-week strategy ($5325.35 vs $2431.71). The added costs of the 8-week strategy resulted in short-term incremental costs per quit of $19,940.68 (range = $2305.02-$33,952.04 across sensitivity analyses) (Table 3).

Lifetime Impact of Counseling and Screening

When the costs and quit results of the 2 counseling intervention strategies delivered in the setting of lung cancer screening were extended over the lifetime and compared with screening alone, both 3-week and 8-week strategies cost less and saved more QALYs than screening alone (Table 4). Compared with 3 weeks of counseling, the incremental costs per additional QALY gained of 8-week counseling approach was $4029 per QALY, and screening alone was dominated. These results were robust when examining lung cancer deaths averted or life-years saved (Supplementary Table 2, available online), assuming the lowest quit rates and/or highest costs for counseling (Figure 1), or assuming the highest background quit rate without intervention (Figure 1) or using bio-verified quit rates at 12-month follow-up (Supplementary Table 3, available online).

Discussion

This is the first study, to our knowledge, to conduct an economic evaluation of a large, national clinical trial of a telephone counseling intervention for smokers at the time of lung cancer screening and to use those data to project the lifetime costs and effects. The costs of the intervention program were modest and primarily driven by counselor time costs and provision of nicotine replacement therapy to smokers at no cost. Compared with screening, the modest quit rates seen in either a 3-week or 8-week telephone counseling program with nicotine replacement led to lower costs and more QALYs than screening alone. The added costs of using an 8-week (vs 3-week) counseling regimen was largely offset by higher quit rates, leading to very low incremental costs per QALY saved over a lifetime. These results provide important evidence for the value of smoking cessation in the setting of lung cancer screening and underscore the need to maintain reimbursement policies supporting this approach for the millions of screening-eligible smokers in the United States.

Previous economic analyses of smoking cessation interventions conducted in health care or community settings have reported costs per quit of less than $4200 (49-52). We extend these results to describing cessation intervention costs among smokers attending lung cancer screening. We found that the costs per quit of a 3-week telephone counseling regimen ($2432) in the setting of screening were similar to past reports of costs in general populations of smokers. The 8-week counseling approach was slightly more costly ($5325 per quit). The higher costs we observed compared with earlier reports may be due to our use of bio-verified rates (vs self-reported in other studies), having older smokers with higher cigarettes per day (CPD), lower rates of readiness to quit, our provision of nicotine replacement therapy at no-cost to smokers for up to 8 weeks, up to 8 sessions of telephone counseling, and our costs being in 2021 dollars.

The cessation rates observed in the trial were modest and somewhat lower than seen in other trials in the health care setting (49-51,53). This is likely because individuals attending lung cancer screening are older, heavier, and longer-term smokers than smokers in the general population, the broad inclusion criteria in which over one-half were not ready to quit smoking at baseline and may have tried cessation interventions before, making them more refractory to these interventions (7,54). Other smoking cessation strategies are now being tested to address these barriers in the lung screening setting, including 7 other clinical trials in the Smoking Cessation at Lung Examination collaboration (7,36,55-62). It will be important to consider the comparative efficacy and costs of a full range of cessation strategies as data become available.

The costs per QALY for tobacco cessation and lung screening were similar to or lower than many other cancer screening modalities. For example, the costs per LYS used to support mammography screening as a covered Medicare benefit was $34,000 to $88,000 in 1989 dollars (63). The costs per QALY of a 10-yearly colonoscopy for colorectal screening was less than $10,000 in 2007 dollars (64). The costs of per life-year saved associated with monotherapy of mild to moderate hypertension in nonelderly population was $16,000 to $72,000 in 1992 US dollars (65). These comparisons suggest that adoption and implementation of smoking cessation programs in the lung cancer screening setting has an acceptable cost at the societal level.

Several of our past modeling studies have assessed the potential impact of hypothetical cessation interventions in the lung screening setting, and the results suggested that adding a cessation intervention to lung cancer screening could extend the benefits of screening alone (12,14,33-35). The current modeling analysis used actual reported results from a telephone counseling trial and confirmed that the costs per quit of telephone counseling with nicotine replacement therapy translated into savings in costs and increases in life-years saved compared with screening alone. This result is due to the impact...
of modest increases in smoking cessation on both lung cancer and other tobacco-related mortality rates, including cardiovascular disease, chronic obstructive pulmonary disease, and other smoking-related cancers (66,67). In addition, cessation results in a reduction of long-term lung cancer–related costs, which further improves cost-effectiveness (13). Given these benefits, the 8-week intervention approach could be considered because it saved the most QALYs and has a low incremental cost per QALY.

Although these results highlight the value of considering long-term health outcomes when investing in implementation of smoking cessation interventions, they also underscore challenging issues in implementation of effective cessation strategies. For instance, the costs of delivering telephone counseling will be borne by health systems, clinics, and quitlines, with a potential negative impact on their budgets, whereas the benefits and cost offset occur downstream in other sectors of the health care system (68). New policies and reimbursement strategies will likely be needed to support dissemination and implementation efforts for smoking cessation and other similar prevention efforts.

This study has several important strengths. We used data collected from a randomized clinical trial in the lung cancer screening setting. One-half of the trial participants were not ready to quit within the next 30 days (37), similar to the US population of smokers eligible for lung cancer screening (5,12). Therefore, this study provides unbiased and generalizable results on the efficacy and costs of a smoking cessation...
Table 3. Costs per biologically verified 6-month quit rate in an 8-week vs 3-week telephone counseling intervention at the time of lung cancer screening

| Strategy                  | Cessation intervention costs dollars (range) | Costs per quit dollars (range)b | Incremental quit rate (range)c | Incremental costs dollars (range)d | Incremental costs per quit dollars (range)e |
|---------------------------|---------------------------------------------|---------------------------------|-------------------------------|-----------------------------------|---------------------------------------------|
|                           | Quit rate percent (95% CI)                  |                                 |                               |                                   |                                             |
| 3-wk counseling           | 5.96 (3.65 to 8.27)                         | 144.93 (116.91-172.96)         | —                             | —                                 | —                                           |
| 8-wk counseling           | 7.14 (4.63 to 9.63)                         | 380.23 (310.80-449.64)         | 1.18 (0.98-5.98)              | 235.3                             | 19 940.68                                   |

aBoth counseling arms were accompanied by nicotine replacement patches. CI = confidence interval.
bRanges for costs per quit were calculated as (lower bound of intervention costs / upper bound of intervention costs).
cRange for incremental quit rate was calculated as (lower bound of 8-week counseling quit rate – lower bound of 3-week counseling quit rate, upper bound of 8-week counseling quit rate – lower bound of 3-week counseling quit rate), with the assumption that 3-week counseling quit rate was lower than that of 8-week counseling.
dRange of incremental costs was calculated as (lower bound of 8-week counseling costs – upper bound of 3-week counseling costs, upper bound of 8-week counseling costs – lower bound of 3-week counseling costs).
eIncremental costs per incremental quit = incremental costs/difference in quit rates from 2 arms; the range was calculated as (lower bound of incremental costs / upper bound of incremental costs); lower bound of incremental quit rate = lower bound of incremental quit rate, upper bound of incremental quit rate = upper bound of incremental quit rate.

Table 4. Model projections of QALYs gained, costs and incremental cost-effectiveness of telephone counseling with lung screening vs lung screening alone per 100 000 screen-eligible population

| Strategy                  | Total costs | Incremental costs" | Total QALYs | Incremental QALYs gained" | Incremental cost-effectiveness |
|---------------------------|-------------|--------------------|------------|--------------------------|-------------------------------|
| 3-wk counseling and screening | $1 336 181 421 | —                  | 2 245 946  | —                        | —                             |
| 8-wk counseling and screening | $1 345 402 980 | $9 221 559        | 2 248 235  | 2 289                    | $4 029                        |
| Screening alone            | $1 351 907 839 | —                  | 2 239 056  | —                        | dominated"c                   |

aAbsolute numbers are per 100 000 screen-eligible population. There are 5109, 5008, and 4977 lung cancer deaths per 100 000 screen-eligible population with screening alone, 3-week and 8-week counseling, respectively. ICER = incremental cost-effectiveness ratio; QALYs = quality-adjusted life-years.
bScreening alone costs more and yields fewer QALYS than screening with 3-week or 8-week telephone counseling, so it is dominated. In other words, adding telephone counseling to screening saves both dollars and life-years.
cThe incremental costs and QALYS were calculated against the 3-week counseling and screening arm. Screening alone was omitted in the final ICER calculations because screening alone was dominated by the 3-week counseling and screening arm.

intervention in the lung cancer screening setting. Additionally, the micro-costing approach captures variation across real-world patients and could be useful to lung cancer screening sites considering implementation of referral to telephone-counseling programs across the country. Additionally, we used a well-established microsimulation model to extend the trial results over a lifetime horizon (12-14). The model was previously validated and used to simulate lung cancer screening strategies for the USPSTF (43).

Despite these strengths, several caveats should be considered in evaluating our results. Because of the model structure and purpose of modeling lung cancer, other tobacco-related conditions are not modeled directly but are captured in otherwise competing mortality by age, sex, and smoking history. Therefore, we cannot readily incorporate quality of life and costs associated with other diseases. Because smoking cessation leads to lower tobacco-related disease incidence (66), higher incremental QALYS and lower incremental costs because of the interventions would be expected if we would consider quality of life and costs of other tobacco-related illnesses because of avoidance of or improvement in these diseases. Furthermore, previous studies have found that anxiety, stress, and depression ultimately decrease after smoking cessation, with overall improvements in quality of life (69,70). However, our model does not include this positive impact of smoking cessation on quality of life, further underestimating the value of smoking cessation interventions considered in our study. Therefore, our estimates presented in this study should be taken as a conservative estimate of the net benefits. Another limitation is that although we used a conservative 6-month bio-verified 7-day point prevalence quit rate, we assumed that cessation is maintained over time, that is, individuals who quit smoking because of intervention will not relapse. Our results were robust based on 12-month quit rates, but relapse remains a risk beyond this time point. It will be important to update our analyses when data on long-term relapse rates become available from clinical trials in the lung screening setting. In addition, our analysis did not include sufficient numbers of racial and ethnic minorities to assess subgroup effects. It will be important to update results when there are more data for the specific groups targeted by current lung screening guidelines, including lighter smokers and African American smokers. Finally, we assumed 100% screening uptake and adherence in our model to evaluate the efficacy of the cessation intervention plus screening. However, screening uptake is far lower than 100% in real-world settings and varies widely by state (71) and smoking status, with higher uptake among former smokers (72). Adherence to recommended annual lung cancer screening and follow-up care also differ by race, baseline screening results, and type of lung screening programs (73). Hence, it will be important to evaluate the impact of real-world implementation of joint screening and cessation programs in the future.

Overall, this study demonstrates that even modest cessation rates achieved with telephone-based cessation interventions with nicotine replacement for smokers attending lung screening can lead to savings in costs and lives compared with...
screening alone and would be considered very cost-effective. Moving forward, it will be critical to test the impact of reimbursement policies that maximize delivery of smoking cessation and conduct dissemination and implementation trials to determine the most feasible and cost-effective smoking cessation interventions in the lung screening setting.

Funding

This study was supported by the National Cancer Institute at the National Institutes of Health (grant numbers R01CA207228 and R01CA207228-S1). Financial support for this study was also provided in part by the National Cancer Institute Grants U01CA199284 and U01CA253858 to Drs Cao, Jeon and Meza and National Cancer Institute of the National Institutes of Health under Award Number K99CA241397 to Dr Jayasekera and R35CA197289, U01CA152958, and U01CA199218 to Dr Mandelblatt.

Notes

Role of the funder: The funders had no role in the design of the study, the collection, analysis, and interpretation of the data, the writing of the manuscript, and the decision to submit the manuscript for publication.

Disclosures: The authors have no conflict of interest to disclose.

Author contributions: Conceptualization—PC, JSM, J Jeon, KLT, RM, J Jayasekera. Data curation—PC, LS. Formal analysis—PC, LS, J Jayasekera. Funding acquisition—JSM, KLT, DTL, RM. Investigation—PC, LS. Methodology—PC, JSM, J Jeon, RM, J Jayasekera. Project administration—PC, LS, KLT, AZ. Supervision—JSM, KLT, DTL, RM, J Jayasekera. Validation—PC, LS, J Jeon, RM, J Jayasekera. Visualization—PC, LS. Writing—original draft: PC, LS, JSM, J Jeon, RM, J Jayasekera. Writing: review & editing: PC, LS, JSM, J Jeon, KLT, AZ, DTL, RMW, RM, J Jayasekera.

Data Availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

1. American Cancer Society. Cancer facts and figures. 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Accessed June 27, 2022.
2. Aberle DR, Adams AM, Berg CD, et al.; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):355-364. doi:10.1056/NEJMoa1010287.
3. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873.
4. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873.
5. Moyer VA; U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160(5):330-338.
6. Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer. 2013;119(7):1381-1385. doi:10.1002/cncr.27913.
7. Krist AH, Davidson KW, Mangione CM, et al.; US Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117.
29. Lichtenstein E, Glasgow RE, Lando HA, Ossip-Klein DJ, Boles SM. Telephone counseling for smoking cessation: a missed teachable moment for smoking cessation. Lung Cancer. 2007;56(1):125-134. doi:10.1016/j.lungcan.2006.11.015.

30. Zeliadt SB, Helftter JR, Sayer G, et al. Attitudes and perceptions about smoking cessation in the context of lung cancer screening. JAMA Intern Med. 2015;175(10):1550-1555. doi:10.1001/jamainternmed.2015.0558.

31. Williams RM, Cordon M, Eyestone E, et al.; the Lung Screening, Tobacco, Cancer Update Collaboration. Cost-effectiveness of smoking cessation interventions in the lung cancer screening setting: a simulation study. J Natl Cancer Inst. 2021;113(6):1056-1073.

32. Meza R, Cao P, Jeon J, et al. Impact of joint lung cancer screening and cessation interventions under the new recommendations of the U.S. Preventive Services Task Force. J Thorac Oncol. 2022;17(5):662-669. doi:10.1016/j.jto.2021.11.061.

33. Fiore MC, Jaeger CR, Levinson W, et al. American Society of Preventive Oncology. 2021 update of the ASPO smoking cessation guidelines. J Natl Cancer Inst. 2020;112(24):1825-1844. doi:10.1093/jnci/djaa411.

34. Yong HH, Borland R, Siahpush M. Quitting-related beliefs, intentions, and motivations of older smokers in four countries: findings from the international tobacco control policy evaluation survey. Addict Behav. 2019;103:104849. doi:10.1016/j.addbeh.2019.10.021.

35. Taylor KL, Williams RM, Li T, et al. A randomized trial of telephone-based smoking cessation treatment in the lung cancer screening setting. J Natl Cancer Inst. 2022;djac127. doi:10.1093/jnci/djac127.

C missionary approach to smoking cessation. Ann Intern Med. 1996;124(3):346-354. doi:10.7326/0003-4819-150-7-200904070-00003.

37. Reisinger SA, Kamel S, Seiber E, Klein EG, Paskett ED, Wewers ME. Cost-effectiveness of smoking cessation treatment in the lung cancer screening setting. Lung Cancer. 2022;197(2):160-166. doi:10.1016/j.lungcan.2021.09.011.

38. Taylor KL, Williams RM, Li T, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. JAMA Netw Open. 2019;2(12):e192153. doi:10.1001/jamanetworkopen.2019.2153.

39. Wood DE, Kazerooni EA, Baum SI, et al. Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(9):1214-1220. doi:10.6004/jnccn.2018.0020.

40. Toumazis I, de Nijs K, Cao P, et al. The cost-effectiveness of the 2021 U.S. Preventive Services Task Force recommendation for lung cancer screening: a comparative modeling approach. JAMA. 2021;325(10):988-997. doi:10.1001/jama.2021.3747.

41. Taylor KL, Borland R, McTavish LE, et al. Patterns of birth cohort-specific smoking histories, 1965–2009. Am J Prev Med. 2019;46(2):e31-e37. doi:10.1016/j.amepre.2013.10.022.

42. Jeon J, Holford TR, Levy DT, et al. Smoking cessation randomized controlled trial in the lung cancer screening setting: the lung screening, tobacco, and health trial. Contemp Clin Trials. 2019;82:25-35. doi:10.1016/j.cct.2019.05.006.

43. Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA. 2014;311(2):164-171.

44. Ali A, Kaplan CM, Derefinko KJ, Klesges RC. Smoking cessation for smokers not ready to quit: meta-analysis and cost-effectiveness analysis. Nicotine Tob Res. 2015;17(4):1258-1265. doi:10.1093/ntr/ntu004.

45. IBM Watson Health. Micromedex Redbook. https://www.micromedexsolutions.com/home/dispatch/sls/true. Accessed November 4, 2020.

46. Bureau of Labor Statistics. May 2020 national occupational employment and wage estimates. https://www.bls.gov/oes/current/oes_stubs.htm. Accessed November 4, 2020.

47. Criss SD, Cao F, Bastani M, et al. Cost-effectiveness analysis of lung cancer screening in the United States: a comparative modeling study. Ann Intern Med. 2019;171(1):79-86.

48. Toumazi I, de Nijs K, Cao P, et al. The cost-effectiveness of the 2021 U.S. Preventive Services Task Force recommendation for lung cancer screening: a comparative modeling approach. J Natl Canc Inst. 2021;113(8):1065-1073.

49. Emmons KM, Puleo E, Mertens A, Gritz ER, Diller L, Li FP. Long-term smoking cessation outcomes among childhood cancer survivors in the Partnership for Health Study. J Clin Oncol. 2009;27(12):56-60. doi:10.1200/JCO.2007.13.0800.

50. Taylor KL, Williams RM, Li T, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. JAMA. 2018;319(11):1058-1069. doi:10.1001/jama.2018.3747.

51. Emmons KM, Puleo E, Mertens A, Gritz ER, Diller L, Li FP. Long-term smoking cessation outcomes among childhood cancer survivors in the Partnership for Health Study. J Clin Oncol. 2009;27(12):56-60. doi:10.1200/JCO.2007.13.0800.

52. Taylor KL, Hagerman CJ, Luta G, et al. Preliminary evaluation of a telephone-based smoking cessation intervention in a dental setting: long-term follow-up. J Am Dent Assoc. 2021;152(10):1499-1506. doi:10.1016/j.adaj.2021.09.043.

53. Rigotti NA, Bitton A, Kelley JK, Hoepner BB, Levy DE, Mort E. Offering population-based tobacco treatment in a healthcare setting. Am J Prev Med. 2011;41(5):498-503. doi:10.1016/j.amepre.2011.07.022.

54. Reisinger SA, Kamel S, Seiber E, Klein EG, Paskett ED, Wewers ME. Cost-effectiveness of community-based tobacco dependence treatment interventions: initial findings of a systematic review. Prev Chronic Dis. 2019;16:190232. doi:10.5888/pcd16.190232.

55. Feldman I, Helgason AR, Johansson P, Tegelberg Å, Nohlet E. Cost-effectiveness of a high-intensity versus a low-intensity smoking cessation intervention in a dental setting: long-term follow-up. BMJ Open. 2019;9(8):e023934. doi:10.1136/bmjopen-2019-029934.

56. Yong HH, Borland R, Siahpush M. Quitting-related beliefs, intentions, and motivations of older smokers in four countries: findings from the international tobacco control policy evaluation survey. Addict Behav. 2005;30(4):777-788. doi:10.1016/j.addbeh.2004.08.023.

57. Fu SS, Rothman AJ, Vock DM, et al. Program for lung cancer screening and tobacco cessation: study protocol for a randomized controlled trial. Trials. 2017;18(1):568. doi:10.1186/s13063-017-2312-x.

58. Taylor KL, Hagerman CJ, Luta G, et al. Preliminary evaluation of a telephone-based smoking cessation intervention in the lung cancer screening setting: a randomized controlled trial. Nicotine Tob Res. 2020;22(3):342-349. doi:10.1093/ntr/ntz335.

59. Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. JAMA. 2018;319(11):1058-1069. doi:10.1001/jama.2018.3747.

60. IBM Watson Health. Micromedex Redbook. https://www.micromedexsolutions.com/home/dispatch/sls/true. Accessed November 4, 2020.
